FDA approves ansuvimab-zykl for Ebola virus infection

On December 21, 2020, the US Food and Drug Administration approved Ebanga (ansuvimab-zykl)¬†for the treatment for Zaire ebolavirus (Ebolavirus) infection in adults and children. Ebanga had been granted US Orphan Drug designation and Breakthrough Therapy designations. Ansuvimab is a human IgG1 monoclonal antibody that binds and neutralizes the virus. The safety and efficacy of Ebanga … Continue reading FDA approves ansuvimab-zykl for Ebola virus infection